Ausdal Financial Partners, Inc. Surface Oncology, Inc. Transaction History

Ausdal Financial Partners, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 08, 2022	SELL	$4.73 - $7.9 $47,300 - $79,000	-10,000 Closed	0 $0
Q1 2021 May 05, 2021	BUY	$7.25 - $13.82 $72,500 - $138,200	10,000 New	10,000 $78,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Ausdal Financial Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ausdal Financial Partners, Inc. with notifications on news.